Alpha Cognition Inc.

• Alpha Cognition Inc.
• Health Care

ACOG

Offering Team

Pre-IPO Investors

Deal Highlights

Alpha Cognition, Inc. (the Company) is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease following the recent NDA submission and pending FDA review and approval and subsequent commercial sales of ALPHA-1062 oral tablet formulation.

The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness. The Company has three additional development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of mild cognitive impairment with TBI. less

Alpha Cognition, Inc. (the Company) is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease following the recent NDA submission and pending FDA review and approval and subsequent commercial sales of More

Deal Tracker

Stock Price